ArticleStem cell research & therapy2026
Adipose stem cells derived extracellular vesicles alleviate retinal excitotoxicity via miR-23a-5p/PLCD1/PKCA/GluA2 axis: a potential therapeutic strategy.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDespite excitotoxicity being a pivotal pathological mechanism in various retinal diseases, effective clinical interventions remain limited. Previous study has shown that adipose stem cell-derived extracellular vesicles (ADSC-EVs) can alleviate glutamate-induced retinal ganglion cells (RGCs) death by suppressing protein kinase C alpha (PKCA) pathway and increasing the expression of α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptors (AMPARs) subunit 2 (GluA2) on the cell membrane, but the mechanisms remain unexplored.
methodsTo clarify the molecular processes involved in ADSC-EVs-mediated intracellular calcium balance, we isolated ADSC-EVs using ultrafiltration and ultracentrifugation, and characterized these vesicles by transmission electron microscopy, nanoparticle tracking analysis, and flow cytometry. Small RNA sequencing was performed on glutamate-injured rat retinal precursor (R28) cells pre-treated with ADSC-EVs or PBS. Through bioinformatic analysis, we identified candidate microRNAs and predicted their potential target genes. The regulatory effects of microRNA were confirmed using propidium iodide staining, Fluo-4AM staining, western blotting, and immunofluorescence. Additionally, the RGCs counting and visual function tests were employed to evaluate the therapeutic efficacy of the microRNA in the glutamate-induced SD rat - animal model.
resultsOur results demonstrated that pre-treatment with ADSC-EVs led to a significant increase in the expression levels of miR-127-3p, miR-181b-1-3p, miR-199a-3p/5p, miR-23a-5p, miR-23b-5p, and miR-486 in R28 cells. Bioinformatic analyses suggest that miR-23a-5p may contribute to regulating the calcium overload by inhibiting the expression of phospholipase C delta 1 (PLCD1). Overexpression of miR-23a-5p or pre-treatment with ADSC-EVs modulated the expression of GluA2 on the cell membrane through inhibiting the PLCD1/PKCA/GluA2 axis, thereby reducing intracellular calcium levels and diminishing R28 cell death. In contrast, inhibition of miR-23a-5p expression partially reversed the regulatory effects of ADSC-EVs on calcium concentration and cell viability. Furthermore, our findings suggest that overexpression of miR-23a-5p in retina alleviated glutamate-induced RGCs death and visual function impairment, whereas suppression of miR-23a-5p exacerbated glutamate-induced RGCs death.
conclusionADSC-EVs delived miR-23a-5p mitigate glutamate-induced RGCs damage by inhibiting the PLCD1/PKCA/GluA2 axis. Targeting this miR-23a-5p-mediated axis may therefore represent a promising therapeutic approach for excitotoxic RGCs injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.